AA
FBRX

ALPS Advisors’s Forte Biosciences FBRX Stock Holding History

ALPS Advisors’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,200
Closed -$264K – 1188
2026
Q1 		$264K Sell
10,200
-89
-0.9% -$2.56K ﹤0.01% 980
2025
Q4 		$281K Buy
+10,289
New +$180K ﹤0.01% 944
2021
Q4 		– Sell
-682
Closed -$50K – 922
2021
Q3 		$50K Sell
682
-30
-4% -$16.6K ﹤0.01% 906
2021
Q2 		$598K Buy
+712
New +$642K 0.01% 496
2019
Q2 		– Sell
-148
Closed -$603K – 886
2019
Q1 		$603K Buy
148
+25
+20% +$96.6K ﹤0.01% 454
2018
Q4 		$379K Buy
123
+29
+31% +$125K ﹤0.01% 648
2018
Q3 		$550K Buy
94
+17
+22% +$64.7K ﹤0.01% 542
2018
Q2 		$270K Buy
77
+6
+8% +$22K ﹤0.01% 885
2018
Q1 		$315K Buy
71
+12
+20% +$55.6K ﹤0.01% 812
2017
Q4 		$225K Buy
59
+7
+13% +$27.9K ﹤0.01% 798
2017
Q3 		$243K Buy
52
+4
+8% +$17.8K ﹤0.01% 743
2017
Q2 		$215K Buy
+48
New +$270K ﹤0.01% 747

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

ALPS Advisors's FBRX Position: Q2 2026 in Review

ALPS Advisors sold out of Forte Biosciences (FBRX) in Q2 2026, closing a stake of 10,200 shares — an estimated $264K sold.

ALPS Advisors first reported a position in FBRX in Q2 2017 and held it in 12 quarters. The position peaked at $603K in Q1 2019. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • ALPS Advisors reported no remaining Forte Biosciences position as of Q2 2026 after selling out during the quarter.
  • ALPS Advisors sold 10,200 Forte Biosciences shares in Q2 2026, an estimated $264K.
  • ALPS Advisors first reported a position in Forte Biosciences in Q2 2017 and held it in 12 quarters.
  • ALPS Advisors's Forte Biosciences position peaked at $603K in Q1 2019.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.